Table 1. Characteristics of the enrolled studies on TP73 G4C14-A4T14 polymorphism and cancer.
| First author | Year | Ethnicity | Genotyping method | Source of control | Cancer type | HWE | Case | Control | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAA | PAB | PBB | HAA | HAB | HBB | |||||||
| Romain et al. | 1999 | Caucasian | PCR | P-B | Neuroblastoma | Y | 31 | 39 | 3 | 94 | 49 | 7 |
| Ahomadegbe et al. | 2000 | Caucasian | PCR | H-B | Breast cancer | Y | 36 | 22 | 1 | 27 | 7 | 0 |
| Ryan et al. | 2001 | Caucasian | PCR | P-B | Esophageal cancer | Y | 42 | 41 | 1 | 72 | 65 | 15 |
| Hamajima et al. | 2002 | Asian | PCR–CTPP | H-B | Esophageal cancer | Y | 67 | 29 | 6 | 133 | 98 | 10 |
| Hamajima et al. | 2002 | Asian | PCR–CTPP | H-B | Gastric cancer | Y | 84 | 51 | 9 | 133 | 98 | 10 |
| Hamajima et al. | 2002 | Asian | PCR–CTPP | H-B | Colorectal cancer | Y | 87 | 50 | 10 | 133 | 98 | 10 |
| Hiraki et al. | 2003 | Asian | PCR–CTPP | H-B | Lung cancer | Y | 109 | 68 | 12 | 130 | 95 | 10 |
| Huang et al. | 2003 | Asian | PCR–CTPP | P-B | Breast cancer | Y | 118 | 64 | 18 | 153 | 112 | 17 |
| Hishida et al. | 2004 | Asian | PCR–CTPP | H-B | Lymphoma | Y | 49 | 43 | 11 | 261 | 152 | 27 |
| Li(a) et al. | 2004 | Caucasian | PCR–CTPP | H-B | SCCHN | N | 399 | 271 | 38 | 773 | 387 | 69 |
| Li(b) et al. | 2004 | Caucasian | PCR | P-B | Lung cancer | Y | 593 | 394 | 67 | 721 | 365 | 53 |
| Niwa(a) et al. | 2004 | Asian | PCR–CTPP | H-B | Cervical cancer | Y | 57 | 52 | 3 | 270 | 150 | 22 |
| Hu et al. | 2005 | Asian | PCR-SSCP | P-B | Lung cancer | Y | 255 | 149 | 21 | 295 | 248 | 45 |
| Niwa(b) et al. | 2005 | Asian | PCR | H-B | Endometrial cancer | Y | 61 | 39 | 14 | 270 | 150 | 22 |
| Pfeifer et al. | 2005 | Caucasian | PCR–RFLP | P-B | Colorectal cancer | N | 113 | 54 | 12 | 159 | 96 | 5 |
| Choi et al. | 2006 | Asian | PCR | P-B | Lung cancer | Y | 320 | 221 | 41 | 338 | 212 | 32 |
| Ge et al. | 2006 | Asian | PCR–RFLP | H-B | Gastric cancer | Y | 146 | 99 | 14 | 391 | 210 | 29 |
| Ge et al. | 2006 | Asian | PCR–RFLP | H-B | Esophageal cancer | Y | 214 | 113 | 21 | 391 | 210 | 29 |
| Zheng et al. | 2006 | Asian | PCR–RFLP | P-B | Cervical cancer | Y | 58 | 22 | 2 | 77 | 19 | 4 |
| Chen et al. | 2008 | Caucasian | PCR–RFLP | P-B | SCCHN | Y | 195 | 111 | 20 | 214 | 115 | 20 |
| Li(c) et al. | 2008 | Caucasian | PCR | H-B | Melanoma | Y | 468 | 287 | 150 | 497 | 302 | 39 |
| Zheng et al. | 2008 | Asian | PCR–CTPP | P-B | Cervical cancer | Y | 71 | 28 | 2 | 77 | 19 | 4 |
| Deo Feo et al. | 2009 | Caucasian | PCR | H-B | Gastric cancer | Y | 84 | 22 | 8 | 214 | 71 | 10 |
| Kang et al. | 2009 | Asian | PCR | P-B | Ovarian cancer | Y | 164 | 74 | 19 | 151 | 92 | 14 |
| Misra et al. | 2009 | Caucasian | PCR | H-B | SCCHN | N | 112 | 176 | 15 | 186 | 124 | 9 |
| Lee et al. | 2010 | Asian | PCR–CTPP | P-B | Colorectal cancer | Y | 183 | 171 | 29 | 271 | 173 | 25 |
| Shirai et al. | 2010 | Asian | PCR–CTPP | H-B | Gastric cancer | Y | 220 | 142 | 26 | 239 | 156 | 24 |
| Arfaoui et al. | 2010 | Caucasian | PCR | P-B | Colorectal cancer | Y | 77 | 47 | 26 | 109 | 73 | 22 |
| Mittal et al. | 2011 | Caucasian | PCR–RFLP | P-B | Prostate cancer | Y | 121 | 56 | 0 | 192 | 66 | 7 |
| Craveiro et al. | 2012 | Caucasian | PCR | P-B | Cervical cancer | Y | 95 | 38 | 8 | 119 | 48 | 9 |
| Sun et al. | 2012 | Asian | PCR–CTPP | P-B | Cervical cancer | Y | 107 | 100 | 11 | 128 | 80 | 12 |
| Umar et al. | 2012 | Caucasian | PCR | P-B | Esophageal cancer | Y | 174 | 70 | 11 | 200 | 51 | 4 |
| Zhou et al. | 2012 | Asian | MALDI-TOF | P-B | Breast cancer | Y | 106 | 59 | 5 | 100 | 67 | 11 |
| Zhang et al. | 2014 | Asian | PCR | P-B | Nasopharyngeal carcinoma | Y | 163 | 116 | 14 | 247 | 120 | 13 |
| Wang et al. | 2014 | Asian | PCR–CTPP | P-B | Lung cancer | N | 101 | 59 | 8 | 102 | 68 | 25 |
| Feng et al. | 2017 | Asian | PCR | H-B | Cervical cancer | Y | 103 | 67 | 10 | 114 | 55 | 11 |
Abbreviations: H-B, hospital based; HWE, Hardy–Weinberg equilibrium; N, polymorphisms did not conform to HWE in the control group; P-B, population based; SCCHN, squamous cell carcinoma of the head and neck; Y, polymorphisms conformed to HWE in the control group.